Statement of Commissioner Rosch, Federal Trade Commission v. Lundbeck Inc.
Date
Matter Number
0810156
By
J. Thomas Rosch, Former Commissioner
Displaying 2221 - 2240 of 3911
Beyond the Numbers: Creating An Inclusive Environment (As Prepared For Delivery)
Opening Remarks of FTC Chairman Jon Leibowitz, Federal Trade Commission Inaugural Diversity Summit
Washington, DC
Date
By
Jon Leibowitz, Former Chairman
The One-Size-Fits-All Approach of the Affordable Care Act
Cornell University Health Policy Symposium
Washington, DC
Date
By
J. Thomas Rosch, Former Commissioner
File
Concurring and Dissenting Statement of Commissioner J. Thomas Rosch Regarding Proposed Revisions to the Part 2 Rules and Rule 4.1(e)
FTC File No. P072104
Date
By
J. Thomas Rosch, Former Commissioner
Remarks before the Stanford University Center for Internet and Society (VIDEO)
Palo Alto, CA
Date
By
Julie Brill, Former Commissioner
Common Ground Conference
Remarks by Commissioner Julie Brill, Before the Western Regional Office and the Arizona Attorney General's Office
Phoenix, AZ
Date
By
Julie Brill, Former Commissioner
File
Common Ground Conference
(19.94 KB)
Statement of Commissioner Rosch, Concurring In Part and Dissenting In Part - In the Matter of McWane, Inc and Star Pipe Products, Ltd, and In the Matter of Sigma Corporation
Date
Matter Number
101 0080b
Docket Number
9351
By
J. Thomas Rosch, Former Commissioner
Privacy at the FTC: A Look Back At 2011
29th Annual Institute on Telecommunications Policy & Regulation
Washington, DC
Date
By
Edith Ramirez, Former Chairwoman
File
Privacy at the FTC: A Look Back At 2011
(45.51 KB)
Opening Remarks of FTC Chairman Jon Leibowitz
As Prepared For Delivery, Face Facts Forum
Washington, DC
Date
By
Jon Leibowitz, Former Chairman
File
Face Facts
Remarks of FTC Commissioner Julie Brill, Facial Recognition Forum
Washington, DC
Date
By
Julie Brill, Former Commissioner
File
Face Facts
(33.83 KB)
Antitrust Evaluation of Pay-for-Delay Settlements: A Persistent Quest for Balance
American Conference Institute's Paragraph IV Disputes Conference
San Francisco, CA
Date
By
J. Thomas Rosch, Former Commissioner
Privacy Implications of Social Media
Remarks of FTC Commissioner Julie Brill, U.S.-China Internet Industry Forum
Washington DC
Date
By
Julie Brill, Former Commissioner
File
Privacy Implications of Social Media
(61.59 KB)
Prepared Statement of the Federal Trade Commission In Connection With Oversight of the Antitrust Enforcement Agencies
Before the Subcommittee on Intellectual Property, Competition, and the Internet of the Committee on the Judiciary, United States House of Representatives
Congressional Session
112th Congress
Date
By
Jon Leibowitz, Former Chairman
File
Testimony
(182.13 KB)
Privacy: A Lesson from the Playroom
Remarks of FTC Commissioner Julie Brill, IAPP Practical Privacy Series
Washington, DC
Date
By
Julie Brill, Former Commissioner
File
Privacy: A Lesson from the Playroom
(65.72 KB)
Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
LaTonya Mitchell, Director, Food and Drug Administration (FDA) Denver District Office; and Dr. Ilisa Bernstein, Acting Director, FDA Office of Compliance to Dr. Gary Arbuckle and Ms. Amy Freeze, theoriginalncgdrops.com and resetthebody.com
Date
By
Mary K. Engle, Associate Director
Mary K. Engle
Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
LaTonya Mitchell, Director, Food and Drug Administration (FDA) Denver District Office; and Dr. Ilisa Bernstein, Acting Director, FDA Office of Compliance to Kevin Wright, HCG Platinum, LLC
Date
By
Mary K. Engle, Associate Director
Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
LaTonya Mitchell, Director, Food and Drug Administration (FDA) Denver District Office; and Dr. Ilisa Bernstein, Acting Director, FDA Office of Compliance to Clint Ethington, HCG Diet Direct LLC
Date
By
Mary K. Engle, Associate Director
Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
LaTonya Mitchell, Director, Food and Drug Administration (FDA) Denver District Office; and Dr. Ilisa Bernstein, Acting Director, FDA Office of Compliance to Richard Matmer, Nutri Fusion Systems LLC
Date
By
Mary K. Engle, Associate Director
Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
LaTonya Mitchell, Director, Food and Drug Administration (FDA) Denver District Office; and Dr. Ilisa Bernstein, Acting Director, FDA Office of Compliance to Greg Grimshaw, hcg-miracleweightloss.com
Date
By
Mary K. Engle, Associate Director
Displaying 2221 - 2240 of 3911
Join us at the FTC!